Equities

Assure Tech Hangzhou Co Ltd

688075:SHH

Assure Tech Hangzhou Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)37.76
  • Today's Change-0.88 / -2.28%
  • Shares traded836.92k
  • 1 Year change-12.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Assure Tech Hangzhou Co Ltd is a China-based company mainly engaged in the research and development of point-of-care testing (POCT) reagents and instruments. The Company's products include antigen and antibody raw materials, immunochromatographic reagents and testing equipment, and dry biochemical reagents and testing equipment. The Company's POCT products cover eight areas of drug testing, infectious disease testing, chronic disease testing, pregnancy testing, tumor testing, myocardial testing, biochemical testing, and allergen testing. The Company's products are sold to the United States, Germany, Britain, Canada and other countries.

  • Revenue in CNY (TTM)590.49m
  • Net income in CNY90.50m
  • Incorporated2008
  • Employees791.00
  • Location
    Assure Tech Hangzhou Co LtdBuilding 4, No. 1418-50Moganshan Road, Gongshu DistrictHANGZHOU 310011ChinaCHN
  • Phone+86 57 181022698
  • Fax+86 57 188865920
  • Websitehttp://www.diareagent.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Getein Biotech Inc1.25bn252.99m4.37bn2.14k17.261.68--3.500.49880.49882.465.120.32411.622.91584,007.906.7313.259.8618.4567.6465.5720.7628.131.69--0.20529.88-24.8514.81-43.922.3118.446.00
Qingdao NovelBeam Technology Co Ltd413.02m124.91m4.40bn797.0035.173.43--10.661.041.043.4410.630.29620.86634.68518,221.708.8114.679.3716.6363.8562.3229.7334.159.12--0.026233.55-1.3118.58-20.1921.7110.45--
Jiangsu Bioperfectus Technologies Co Ltd394.84m-170.68m4.59bn684.00--1.40--11.62-2.91-2.916.7458.000.0970.97472.52577,244.10-4.1925.41-4.7431.2665.7063.37-43.2332.864.96--0.090330.54-92.7211.81-120.45--2.43--
TINAVI Medical Technologies Co Ltd168.49m-160.48m4.60bn339.00--3.90--27.29-0.3585-0.35850.37562.620.10751.484.73475,961.90-10.24-7.86-11.04-9.0768.6673.58-95.24-50.092.21--0.1532--34.4810.63-41.42--51.87--
Assure Tech Hangzhou Co Ltd590.49m90.50m4.80bn791.0053.040.9316--8.130.7120.7124.6540.530.10111.902.85746,504.601.5531.831.7138.9736.8765.8215.3047.868.66--0.012516.05-91.8425.18-95.3533.5178.77--
Beijing Chunlizhengda Mdicl Instr Co Ltd924.65m158.35m4.82bn1.23k34.751.94--5.210.40780.40782.417.290.26980.53812.15751,138.904.6212.535.4915.4371.0872.7617.1226.893.80--0.000321.630.575919.40-9.7221.33-8.60--
Zhejiang Gongdong Medical Techno Co Ltd1.10bn162.27m4.90bn1.67k30.172.94--4.461.031.036.9510.570.56846.554.33656,174.208.4016.359.7119.2632.4841.1914.7721.623.00--0.052138.99-33.6115.11-66.535.1427.71--
Hangzhou Ags Medtech Co Ltd590.12m271.52m4.95bn592.0018.212.15--8.393.363.367.3028.530.25453.2713.92996,828.3011.71--12.26--71.52--46.01--19.56--0.003--37.09--49.87------
Xiangyu Medical Co Ltd709.56m121.39m5.18bn1.82k42.022.56--7.300.770.774.5212.660.25961.0114.80390,085.104.4411.185.6213.1266.0366.7817.1232.691.43--0.141727.3352.4615.7281.0323.11132.76--
Hangzhou Alltest Biotech Co Ltd812.78m276.54m5.25bn1.09k18.941.32--6.463.503.5010.2650.020.1982.216.97743,626.506.7423.357.2226.8353.6958.3434.0339.0710.46--0.002229.79-77.7332.59-84.7526.1972.77--
Shanghai Sanyou Medical Co Ltd434.20m37.87m5.26bn466.00147.822.75--12.110.14320.14321.717.690.19510.61915.15931,756.402.099.422.4110.8570.7287.1510.7329.783.27--0.013516.21-29.0815.67-49.918.99-15.60--
Data as of Nov 15 2024. Currency figures normalised to Assure Tech Hangzhou Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

13.97%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 30 Jun 20242.51m7.99%
Rongtong Fund Management Co., Ltd.as of 30 Jun 2024700.79k2.23%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024696.75k2.22%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024196.17k0.63%
Taikang Asset Management Co. Ltd.as of 30 Jun 2024170.00k0.54%
JX Asset Management Co.,Ltdas of 30 Jun 202443.00k0.14%
E Fund Management Co., Ltd.as of 30 Jun 202435.26k0.11%
Guotai Asset Management Co., Ltd.as of 30 Jun 202416.15k0.05%
Nuode Asset Management Co., Ltd.as of 30 Jun 202412.26k0.04%
Manulife TEDA Fund Management Co., Ltd.as of 30 Jun 20248.07k0.03%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.